Federal court invalidates Sanofi's Plavix patent for alleged insufficiency and obviousness.
نویسنده
چکیده
On December 6, 2011, the Federal Court of Canada issued its decision1 in the well-known dispute between Apotex Inc. and Sanofi-Aventis over the anticoagulant drug, clopidogrel bisulfate, sold in Canada under the brand name Plavix. This compound is a single enantiomer of a previously disclosed racemate. The Court invalidated Sanofi’s patent (Canadian patent no. 1,366,777, “the ′777 Patent”). An appeal has been filed by Sanofi.
منابع مشابه
A New Formula for Analyzing Formulation-patent Obviousness
The generic drug industry, which is estimated to save American consumers $10 billion a year,1 owes much of its current market success to Congress’s enactment of the Hatch-Waxman Act in 1984.2 The Hatch-Waxman Act sought to achieve a delicate balance, one where Americans could obtain unprecedented access to low-cost prescription medicine without somehow undermining the incentive of brand name dr...
متن کاملKSR v. Teleflex. Part 1: Impact of U.S Supreme Court Patent Law on Canadian intellectual property and regulatory rights landscape.
In KSR, SCOTUS retooled the standard for obviousness to bring it back in line with the court's previous decisions in Hotchkiss and Graham. A comparative review of the law of obviousness in the United States and Canada, and its relation to innovation and competition, was undertaken in Sections II and III. The focal point of observed differences is the inherent creativity and inventiveness of the...
متن کامل“genius of Art
2 as a critical element of the United States patent system. The requirement mandates that, at the time of invention, an invention must not have been obvious to a person having ordinary skill in the art. In effect, this screens routine improvements out of the patent system and rewards inventions perceived to be scientific breakthroughs. Recent Supreme Court cases developing non-obviousness highl...
متن کاملFormulation Patents and Dermatology and Obviousness
Most patents covering dermatologic products contain patent claims directed to the pharmaceutical formulation of the product. Such patents, known as formulation patents, are vulnerable to attacks based on the legal argument that the formulations covered are obvious over formulations already known prior to the filing of the patent application. Because obviousness is an important concept in patent...
متن کاملKSR Int’l Co. v. Teleflex, Inc.: No Obvious Changes for the Biotechnology Market
With the advent of molecular biology, genomics, and proteomics, the intersection between science and law has become increasingly significant. In addition to the ethical and legal concerns surrounding the collection, storage, and use of genomic data, patent disputes for new biotechnologies are quickly becoming part of mainstream business discussions. Under current patent law, new technologies ca...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
- Health law in Canada
دوره 32 3 شماره
صفحات -
تاریخ انتشار 2012